Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
COLUMN
Plant the Seeds of Success when Battling a Crisis
In my home country of Australia, there is a famous candy called “Minties”. Minties has a long-running advertising campaign, presenting comical situations, with the caption, “It’s moments like these.” The phase has become part of the Aussie vernacular, meaning in…
To read the full story
COLUMN
- Build a Strong Employer Brand - What Can You Do If Your Company Stinks?
March 19, 2025
- 4 Things Your Firm Can Do to Attract and Retain Top Talent in Japan’s Pharmaceutical and Medical Device Industry
February 14, 2025
- A Conversation with Bill Schuster: Navigating the Complexities of Healthcare Leadership
January 24, 2025
- A Conversation with James Feliciano: Navigating the Complexities of the Japanese Pharmaceutical Industry
December 23, 2024
- How to Be a Country Manager
November 29, 2024
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…